Compare Bristol-Myers Squibb Co (BMY) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs The Coca-Cola Co K — how do they compare? Bristol-Myers Squibb Co trades at $63.41 (market cap $129.94B), while The Coca-Cola Co K trades at $86.32 (market cap $372.08B). The key difference: The Coca-Cola Co K is far larger — about 2.9× Bristol-Myers Squibb Co's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | KO | |
|---|---|---|
Market Cap | $129.94B | $372.08B |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $89.08 |
52-Week Low | $42.60 | $65.67 |
Enterprise Value | $163.92B | $399.26B |
Dividend Yield | 3.96% | 2.45% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
